258 related articles for article (PubMed ID: 20046420)
21. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
22. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Saif MW; Sandoval A
Cutan Ocul Toxicol; 2008; 27(4):311-5. PubMed ID: 19037763
[TBL] [Abstract][Full Text] [Related]
23. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Tavares-Bello R
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
[No Abstract] [Full Text] [Related]
25. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Hénin E; You B; VanCutsem E; Hoff PM; Cassidy J; Twelves C; Zuideveld KP; Sirzen F; Dartois C; Freyer G; Tod M; Girard P
Clin Pharmacol Ther; 2009 Apr; 85(4):418-25. PubMed ID: 19078948
[TBL] [Abstract][Full Text] [Related]
26. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
28. [Management of hand-foot syndrome in patient treated with capecitabine].
Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
[TBL] [Abstract][Full Text] [Related]
29. Candidate mechanisms for capecitabine-related hand-foot syndrome.
Milano G; Etienne-Grimaldi MC; Mari M; Lassalle S; Formento JL; Francoual M; Lacour JP; Hofman P
Br J Clin Pharmacol; 2008 Jul; 66(1):88-95. PubMed ID: 18341672
[TBL] [Abstract][Full Text] [Related]
30. [Study of tolerability of capecitabine in postoperative adjuvant chemotherapy in colon cancer].
Matsuda C; Tamagawa H; Nishikawa K; Deguchi T; Kawata J; Iwase K; Takagi M; Fukui A; Nezu R; Tanaka Y
Gan To Kagaku Ryoho; 2013 Mar; 40(3):327-30. PubMed ID: 23507593
[TBL] [Abstract][Full Text] [Related]
31. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
32. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
33. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
[TBL] [Abstract][Full Text] [Related]
35. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
36. Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
Emi Y; Kakeji Y; Oki E; Saeki H; Ando K; Kitazono M; Sakaguchi Y; Morita M; Samura H; Ogata Y; Akagi Y; Natsugoe S; Shirouzu K; Tokunaga S; Sirzen F; Maehara Y;
Int J Clin Oncol; 2013 Apr; 18(2):254-9. PubMed ID: 22240888
[TBL] [Abstract][Full Text] [Related]
37. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Lassere Y; Hoff P
Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
40. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
Glen H; Cassidy J
Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
